Table 2.
Prevalence of renal calculi in patients with IBD.
| Subgroup analysis | Studies | Prevalence (95% CI) | Heterogeneity | |
|---|---|---|---|---|
| IBD | CD | 8 | 7.9% (3.1% to 18.7%) | I2 = 95.83%, P < .001 |
| UC | 5 | 5.6% (3.9%–7.8%) | I2 = 81.62%, P < .001 | |
| Un-specified | 11 | 5.6% (3.8%–8.1%) | I2 = 98.45%, P < .001 | |
| Stone location-IBD | Urolithiasis | 5 | 7.1% (3.2–15.2) | I2 = 99.57%, P < .001 |
| Nephrolithiasis | 3 | 2.1% (0.3–12.8) | I2 = 99.65%, P < .001 | |
| Both | 3 | 11.0% (6.5–18.1) | I2 = 50.52%, P = .132 | |
| Stone location-UC | Urolithiasis | 6 | 6.8% (3.3–13.4) | I2 = 98.86%, P < .001 |
| Nephrolithiasis | 2 | 4.2% (2.1–8.1) | I2 = 77.72%, P = .034 | |
| Both | 3 | 9% (2.1–31.0) | I2 = 45.82%, P = .158 | |
| Stone location-CD | Urolithiasis | 6 | 7.1% (3.6–13.6) | I2 = 99.17%, P < .001 |
| Nephrolithiasis | 2 | 4.6% (3.6–5.8) | I2 = 0.00%, P = .812 | |
| Both | 3 | 11.9% (8.4–16.6) | I2 = 0.00%, P = .774 | |
| Study design | Cohort | 19 | 6.9% (5.0%–9.4%) | I2 = 98.19%, P < .001 |
| Case-control | 5 | 4.1% (3.0%–5.6%) | I2 = 49.02%, P = .097 | |
| Year of publication | From inception to the end of 2009 | 14 | 7.3% (4.8%–11.0%) | I2 = 92.23%, P < .001 |
| From 2010–2022 | 10 | 5.2% (3.5%–7.5%) | I2 = 98.51%, P < .001 | |
CD = Chron’s disease, CI = Confidence interval, IBD = inflammatory bowel disease, UC = Ulcerative colitis.